Malignancies Multiple
Conditions
Keywords
relapsed or refractory, malignancies, decitabine, anti-PD-1 antibody, chemotherapy
Brief summary
The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.
Detailed description
Primary objective: To assess the feasibility and safety for Anti-PD-1 antibody alone or in combination with decitabine and/or chemotherapy administered every 3 weeks to subjects with relapsed or refractory malignancies. Secondary objectives: 1) To assess the antitumor activity of Anti-PD-1 antibody alone or in combination with decitabine and/or chemotherapy in subjects with relapsed or refractory malignancies. 2) To characterize the immunological effects of Anti-PD-1 antibody alone or in combination with decitabine and/or chemotherapy. 3) To characterize the immunological effects of Anti-PD-1 antibody alone or in combination with decitabine and/or chemotherapy. Exploratory objectives: 1) To analysis of potential biological parameters correlated to clinical response and toxicities. 2) To search predictive biomarkers to guide the choose of patients undergoing the treatment of Anti-PD-1 antibody alone or in combination with decitabine and/or chemotherapy. Safety Evaluation: Adverse events will be assessed continuously during the study and for 100 days post last treatment, and will be evaluated according to the NCI CTCAE Version 4.0. Efficacy Evaluation: 1) Treatment response to lymphoma was defined using the International Workshop to Standardize Response Criteria for Lymphomas; 2) Treatment response to solid tumors was defined using Response Evaluation Criteria in Solid Tumors (RECIST1.1). evaluation index: BOR; ORR; PFS and OS.
Interventions
Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
DRUGDecitabine
Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
DRUGChemotherapy
Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
Sponsors
Han weidong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects must have histological confirmation of relapsed or refractory malignancies,including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer. 2. 12 to 75 years of age. 3. ECOG performance of less than 2. 4. Life expectancy of at least 3 months. 5. Subjects with lymphoma must have at least one measureable lesion \>1 cm as defined by lymphoma response criteria; with solid tumors must have at least one measureable lesion \>1 cm per RECIST1.1. 6. Subjects must have received at least two prior chemotherapy regimen, and must be off therapy for at least 4 weeks prior to Day 1. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months. 7. Subjects must have adequate bone marrow, live, renal, lung and heart functions. 1. Absolute neutrophil count greater than or equal to 1,000/μL. 2. Platelet count greater than or equal to 70,000/µL. 3. Serum bilirubin level less than or equal to 1.5 x upper limits of normal (ULN). 4. Serum creatinine less than or equal to 1.5 x ULN. 5. Alanine aminotransferase \[ALT or SGPT\] and aspartate aminotransferase \[AST or SGOT\] less than or equal to 2.5 x ULN.
Exclusion criteria
1. Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications. 2. Serious uncontrolled medical disorders or active infections, pulmonary and intestinal infection especially. 3. Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in 1 month . 4. Prior organ allograft. 5. Women who are pregnant or breastfeeding. 6. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Objective response by Response Evaluation Criteria in Solid Tumors (RECIST1.1). | 3 years |
| Objective response by the International Workshop to Standardize Response Criteria for lymphomas. | 3 years |
| Progression free survival | 5 years |
| Overall survival | 5 years |
Countries
China
Contacts
CONTACTWeidong Han, doctor
CONTACTQingming Yang, doctor
STUDY_DIRECTORChunmeng Wang, Master
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
STUDY_DIRECTORWenying Zhang, Master
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
STUDY_DIRECTORYang Liu, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
STUDY_DIRECTORMeixia Chen, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
PRINCIPAL_INVESTIGATORYan Zhang, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
STUDY_DIRECTORQian Mei, Doctor
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
STUDY_DIRECTORJing Nie, Doctor
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
PRINCIPAL_INVESTIGATORXiang Li, Master
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
PRINCIPAL_INVESTIGATORLiang Dong, Master
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
PRINCIPAL_INVESTIGATORLu Shi, Master
Department of Molecular Biology, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
PRINCIPAL_INVESTIGATORKaichao Feng, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
PRINCIPAL_INVESTIGATORJingdan Qiu, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
PRINCIPAL_INVESTIGATORHejin Jia, Doctor
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China, 100853
Outcome results
None listed